Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women... DOI: 10.1111/hiv.12468 © 2016 British HIV Association HIV Medicine (2017), 18, 56--63 ORIGINAL RESEARCH Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients 1,2 3 1 3,4 5 1 3,4 C Hoffmann, T Welz, M Sabranski, M Kolb, E Wolf, H-J Stellbrink and C Wyen 1 2 ICH Study Center Hamburg, Hamburg, Germany, Department of Medicine II, University of Schleswig-Holstein, Kiel, 3 4 Germany, Praxis am Ebertplatz, Cologne, Germany, Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany and MUC Research GmbH, Munich, Germany Objectives Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is now among the most frequently used antiretroviral agents. However, recent reports have raised concerns about potential neurotoxicity. Methods We performed a retrospective analysis of a cohort of HIV-infected patients who had initiated an INSTI in two large German out-patient clinics between 2007 and 2016. We compared discontinuation rates because of adverse events (AEs) within 2 years of starting treatment with dolutegravir, raltegravir or elvitegravir/cobicistat. We also evaluated factors associated with dolutegravir discontinuation. Results A total of 1950 INSTI-based therapies were initiated in 1704 patients eligible for analysis within the observation period. The estimated rates of any AE http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Hiv Medicine Wiley

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

Loading next page...
 
/lp/wiley/higher-rates-of-neuropsychiatric-adverse-events-leading-to-dJieRdfkdz

References (17)

Publisher
Wiley
Copyright
HIV Medicine © 2017 British HIV Association
ISSN
1464-2662
eISSN
1468-1293
DOI
10.1111/hiv.12468
pmid
27860104
Publisher site
See Article on Publisher Site

Abstract

DOI: 10.1111/hiv.12468 © 2016 British HIV Association HIV Medicine (2017), 18, 56--63 ORIGINAL RESEARCH Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients 1,2 3 1 3,4 5 1 3,4 C Hoffmann, T Welz, M Sabranski, M Kolb, E Wolf, H-J Stellbrink and C Wyen 1 2 ICH Study Center Hamburg, Hamburg, Germany, Department of Medicine II, University of Schleswig-Holstein, Kiel, 3 4 Germany, Praxis am Ebertplatz, Cologne, Germany, Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany and MUC Research GmbH, Munich, Germany Objectives Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is now among the most frequently used antiretroviral agents. However, recent reports have raised concerns about potential neurotoxicity. Methods We performed a retrospective analysis of a cohort of HIV-infected patients who had initiated an INSTI in two large German out-patient clinics between 2007 and 2016. We compared discontinuation rates because of adverse events (AEs) within 2 years of starting treatment with dolutegravir, raltegravir or elvitegravir/cobicistat. We also evaluated factors associated with dolutegravir discontinuation. Results A total of 1950 INSTI-based therapies were initiated in 1704 patients eligible for analysis within the observation period. The estimated rates of any AE

Journal

Hiv MedicineWiley

Published: Jan 1, 2017

Keywords: ; ; ; ; ;

There are no references for this article.